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Neurobiology of Disease
Bcl-x Pre-mRNA Splicing Regulates Brain Injury after
Neonatal Hypoxia-Ischemia
Qingli Xiao, Andria L. Ford, Jan Xu, Ping Yan, Kuang-Yung Lee, Ernesto Gonzales, Tim West, David M. Holtzman,
and Jin-Moo Lee
Hope Center for Neurological Disorders and Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110
The bcl-x gene appears to play a critical role in regulating apoptosis in the developing and mature CNS and following CNS injury. Two
isoforms of Bcl-x are produced as a result of alternative pre-mRNA splicing: Bcl-xL (the long form) is anti-apoptotic, while Bcl-xS (short
form) is pro-apoptotic. Despite the antagonistic activities of these two isoforms, little is known about how regulation of alternative
splicing of bcl-x may mediate neural cell apoptosis. Here, we report that apoptotic stimuli (staurosporine or C2-ceramide) reciprocally
altered Bcl-x splicing in neural cells, decreasing Bcl-xL while increasing Bcl-xS. Specific knockdown of Bcl-xS attenuated apoptosis. To
further define regulatory elements that influenced Bcl-x splicing, a Bcl-x minigene was constructed. Deletional analysis revealed several
consensus sequenceswithin intron 2 that altered splicing.We found that the splicing factor, CUG-binding-protein-1 (CUGBP1), bound to
a consensus sequence close to the Bcl-xL 5 splice site, altering the Bcl-xL /Bcl-xS ratio and influencing cell death. In vivo, neonatal
hypoxia–ischemia reciprocally altered Bcl-x pre-mRNA splicing, similar to the in vitro studies.Manipulation of the splice isoforms using
viral gene transfer of Bcl-xS shRNA into the hippocampus of rats before neonatal hypoxia–ischemia decreased vulnerability to injury.
Moreover, alterations in nuclear CUGBP1precededBcl-x splicing changes. These results suggest that alternative pre-mRNAsplicingmay
be an important regulatory mechanism for cell death after acute neurological injury and may potentially provide novel targets for
intervention.
Introduction
Hypoxic–ischemic insults to the perinatal brain frequently lead
to severe brain injurywith resultant intellectual impairment,mo-
tor disability, and seizures at later ages. Animal studies have
shown that the mechanisms leading to injury in the developing
brain are distinct from those involved in adult brain injury (Back
et al., 2002; McQuillen et al., 2003). Though not an exclusive
injury mechanism, apoptosis appears to play a prominent role in
neonatal hypoxia–ischemia (H–I), as this cascade is easily en-
gaged after brain insults during this developmental stage (Pulera
et al., 1998; Nakajima et al., 2000). A proximal and important
regulator of apoptosis is the mitochondrial protein Bcl-xL, which
is highly expressed during embryonic development in the CNS.
Deletion of bcl-x, the gene that encodes Bcl-xL, in mice results in
massive neuronal death in the brain, spinal cord, and dorsal root
ganglia during late embryonic development (Motoyama et al.,
1995), indicating that bcl-x is important for neuronal survival.
Moreover, Bcl-xL overexpression attenuates brain injury caused
by a variety of CNS insults, including H–I in neonatal rodents
(Parsadanian et al., 1998; Wiessner et al., 1999; Cao et al., 2002;
Yin et al., 2006).
The bcl-x gene generates two protein products with opposing
actions as a result of alternative pre-mRNA splicing: Bcl-xL (the
longer form) is anti-apoptotic, while Bcl-xS (the short form) is
pro-apoptotic. Recent studies in a variety of cancer cell lines have
shown that Bcl-xL appears to be reciprocally regulatedwith Bcl-xS
following apoptotic stimuli, suggesting that alternative pre-
mRNA splicing of Bcl-x pre-mRNA may be a critical regulator of
programmed cell death. Treatment of A549 adenocarcinoma
cells with the apoptosis-inducing agent ceramide resulted in in-
creased Bcl-xS and a concomitant decrease in Bcl-xL mRNA
(Chalfant et al., 2002). Two cis-elements (CRCE1 and CRCE2)
within exon 2 were shown to be necessary for ceramide-induced
splicing effects (Massiello et al., 2004), and SAP155was identified
as the splicing factor that bound to CRCE1, inducing A549 cell
death (Massiello et al., 2006). Other groups have demonstrated
that altering pre-mRNA splicing of Bcl-x, using antisense oligo-
nucleotides targeted at the Bcl-xL splice site, increased suscepti-
bility to cell death (Taylor et al., 1999; Mercatante et al., 2001;
Villemaire et al., 2003). Indeed, it has been proposed that a crit-
ical ratio of Bcl-xL to Bcl-xS is required to maintain cell survival
(Minn et al., 1996).
While several studies have investigated Bcl-x pre-mRNA
splicing in vitro using cell lines, few have explored its role in vivo
in apoptosis or other pathological models of injury. Moreover,
there are no studies that have demonstrated a requirement for
endogenous Bcl-xS expression in cell death. In this study, we
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sought to determine whether the regulation
of Bcl-x alternative pre-mRNA splicing was
an important mechanism of neural cell
death following neonatal H–I.
Materials and Methods
Cell culture and death assessment. Rat oligoden-
drocyte progenitor (OP) cells were cultured as
described previously (Zhang et al., 1999), with
slight modifications. The cells were grown
in progenitor medium (69% DMEM/F-12/
HEPES containingN1 supplement, 10g/ml in-
sulin, 20 nM progesterone, 100 units penicillin-
streptomycin, 30% conditioned medium from
B104 cells, and 1% FBS) and plated on 100 mm
culture dishes precoated with poly-L-lysine. Dis-
aggregated oligosphere cells displayed bipolar or
tripolar morphology. OP cells were maintained
in growth medium and treated with various
concentrations (0–100 M) of C2-ceramide
(Biomol) for varying times. Cell viability was as-
sessed by lactate dehydrogenase (LDH) and the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetra-
zoliumbromide (MTT) assay as described previ-
ously (Xu et al., 2000). For DNA laddering,
OP cells were homogenized and incubated in
a lysis buffer containing RNase A and protei-
nase K overnight at 37°C. After extraction,
DNA pellets were dissolved in Tris-EDTA
buffer and electrophoresed and visualized by
UV light. Caspase activity was measured us-
ing a colorimetric assay kit, CaspACE assay
system (Promega).
Pure neuronal cultures were prepared from
the cortices of embryonic day 15 (E15) mice.
Cortices were collected, digested with 0.25%
trypsin, triturated, then plated in Neurobasal
medium (Invitrogen) supplemented with B27
and 25 M glutamate. Cultures were kept at
37°C in a humidified incubator with 5% CO2.
Oxygen–glucose deprivation was performed
as described previously (Xu et al., 2000).
Briefly, cortical neuronswere transferred into a
temperature-controlled (37  1°C) anaerobic
chamber containing a gas mixture composed
of 5%CO2, 10%H2, 85%N2, and 0.1%O2. The
cultures were washed three times with deoxy-
genated glucose-freeHBSS and then kept in the
same medium in the hypoxia chamber for 90
min followed by reoxygenation in a normoxic
incubator under 5% CO2/95% air for 3–24 h.
Cells exposed toHBSS in a normoxic incubator
served as a control.
Construction of minigene and splicing factor ex-
pression vectors. The minigenes were constructed
by amplifying regions of the bcl-x gene from rat
genomic DNA by PCR using primers containing
unique NheI, EcoRI, BglII, and XhoI restriction
sites to allow replacement of segments of the
minigene as cassettes. Briefly, the 2.6 kb fragment
of bcl-x containing 3-end of exon 1, intron 1, exon 2 and 5-end of intron 2
was generated using a forward primer: Nf, 5-ATTCCGCTAGCCTGCCTA
CCAGGTC-3, and a reverse primer: Er, 5-CTGGAATTCTGCCCCTCC
TATAATCAGC-3 (restriction sites are underlined). Another 0.5 kb
fragment of bcl-x containing 3-end of intron 2 and 5-end of exon 3 was
generated by forward primer: Ef, 5-AGAAGAATTCTCTGTCTGAA
AGTCC-3, and reverseprimer:Xr, 5-AGGCTCGAGCGGTTGAAACG
CTCCTGGC-3. Both of the aforementioned fragments were ligated and
inserted between the NheI and XhoI sites of pcDNA3.1 vector (Invitro-
gen), which contains the CMV promoter. Intron 2 deleted constructs
were generated by PCR using the common forward primer Nf and fol-
lowing reverse primers: D1 (5-GGAGAATTCGCTACTCTCCTAGGT
T-3), D2 (5-AGCCAGAATTCAAAATACAGGTTCC-3), D3 (5-CC
TGAATTCTCGATATCTTCAACAAC-3), D4 (5-AGGGAATTCCAC
AGAGGAGAGACACAC-3), D5 (5-GGCGGATTCACAAGGGGCGT
GGTTCT-3). For U/G motif truncated construct, the upstream
fragment was produced by Nf and a reverse primer Bgr, 5-CTGAGATC
Figure 1. Changes in Bcl-x alternative splicing during apoptosis. A, Oligodendrocyte precursor (OP) cells were treated with
varying concentrations of C2-ceramide as indicated for 24 h. Total RNA was extracted and analyzed by RT-PCR for alternative
splicing of Bcl-x (noted below the gels are the Bcl-xL/Bcl-xS ratios). The bottom graphs show cell death by LDH release. B, OP cells
were treated with 50 M C2-ceramide for varying times as indicated. Total RNA was extracted and analyzed by RT-PCR for
alternative splicing of Bcl-x, and Bcl-xL/Bcl-xS ratios were quantified. C–F, OP cells were treated with 50 M C2-ceramide for
varying times and immunoblotted for Bcl-xL and Bcl-xS (C), assayed for caspase-3 activity (D), DNA fragmentation (E), and cell
survival (MTT) and death (LDH) (F ). Data were expressed as mean SE of three independent experiments. G, Cortical neurons
were treated with 40M C2-ceramide or 100 nM staurosporine for 24 h or oxygen glucose deprivation for 90 min, followed by
reoxygenation for varying times (3–24 h as indicated). Shown are RT-PCR products showing reciprocal changes in Bcl-x splice
isoforms.
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TGGGGCGTGGTTC-3. The downstream fragment was generated by
Xr and a forward primer Bgf, 5-CTTAGATCTCTCTTCCTCTGT-3.
The above two PCR fragments were ligated and cloned into pcDNA3.1
digested with NheI and XhoI. Site-directed mutagenesis of bcl-x mini-
gene was performed using the GeneTailor mutagenesis kit (Invitrogen)
and the following primer: 5-CCTTGACTGTCCGCCCCTTGACTGTC
TCTCCTCT-3. cDNA sequence of the CUG-binding protein CUGBP1
(NM_006560) was PCR amplified using a forward primer: 5-CTCAGC
TAGCAGAAAATGAACGGCAC-3, and a reverse primer: 5-CAGAAT
TCAGCACGCTCAGTAGGGCT-3 and subcloned into pcDNA3.1
vector with BamHI and EcoRI restriction sites. All constructs were con-
firmed by sequence analysis.
Cell transfection and RT-PCR. Cells were transfected with the minigene
with or without a CUGBP1 expression vector using Lipofectamine 2000
(Invitrogen). After 36–48h, transfected cellswerewashedwith ice-coldPBS
and harvested. Cells or frozen brain tissues were homogenized and total
RNAwas isolatedusingTRI reagent (MolecularResearchCenter) according
to themanufacturer’s protocol. Twomicrograms of total RNAwas reverse-
transcribed with 200 units of reverse transcriptase (Promega) and 0.5g of
oligo(dT)15 in a total reaction volume of 20 l under the conditions pro-
vided by the manufacturer’s protocol. To assess endogenous Bcl-x expres-
sion, a PCR with 5-TTGGACAATGGACTGGTTGA-3 (forward) and 5-
CGGCTCTCGGGTGCTGTATTGTTC-3 (reverse) was performed. To
measure the level of minigene-derived mRNA isoforms, the Bcl-x
exon 2 forward primer (5-AGTTTGGATGCGCGGGAGGTAATC-3)
andpcDNA3.1reverseprimerBGHRev(5-TAGAAGGCACAGTCGAGG-
3) were used. PCR products were electrophoretically separated, and the
Bcl-xL/Bcl-xS mRNA ratio was calculated.
RNA interference. For knockdown of Bcl-xS, the paired Bcl-xS shRNA





A complementary pair of scrambledoligonucleotideswas used as control.
Two siRNA sequences (synthesized by Integrated DNATechnologies) were
used to target ratCUGBP1: si-1 sense sequence (5-CCAGAUCUUGAUGC
UAUCAdTdT-3) and antisense sequence (5-UGAUAGCAUCAAGAUC
UGGdTdT-3); si-2sensesequence(5-UGUAACAAAACAGCACCCUdTd
T-3) and antisense sequence (5-AGGGUGCUGUUUUGUUACAdTdT-
3). Duplex siRNA was transfected into OP cells at 200 nM using
Lipofectamine 2000 (Invitrogen). RNA or protein was extracted 48 h
after transfection.
Cell fractionation and immunoblotting. Nuclear and cytosolic protein
extracts were prepared as described (Xu et al., 1997; Yin et al., 2002).
Briefly, tissue or cells were harvested and resuspended in 5 volumes of
buffer A (20 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 1 mM EDTA, 1 mM
EGTA, 250 mM sucrose, 0.1 mM PMSF, 1 mM DTT, and 1 protease
inhibitor cocktail, pH 7.9). After 10 min on ice, cells were homogenized
and centrifuged at 750 g for 15 min at 4°C; the supernatant (cytosolic
extracts) was collected and subjected to centrifugation at 15,000 g for
30 min to remove cellular debris. The nuclear pellet was washed three
times with the same lysis buffer, resuspended in 45l of buffer B (20 mM
HEPES, 1.5 mM MgCl2, 20 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM
PMSF, 1 protease, and phosphatase inhibitor cocktail, pH 7.9), and 15
l of bufferC (20mMHEPES, 1.2MKCl, 0.2mMEDTA, 0.5mMDTT, 0.2
mM PMSF, 1 protease, and phosphatase inhibitor cocktail, pH 7.9) was
added. Samples were placed on ice for 30 min, centrifuged at 15,000 g;
supernatants (nuclear protein) were stored at 80°C. Five micrograms
of nuclear proteins and 20–60 g of cytosolic or total proteins were
subjected to SDS-PAGE and transferred to PVDFmembranes for detect-
ing proteins using the following antibodies: Bcl-x (GenScript), CUGBP1
(Novus Biologicals), caspase-3 (Cell Signaling Technology), and actin
(Sigma).
Electrophoretic mobility shift assay and UV cross-linking analysis. An RNA
oligo containing U/G motif, 5-CUUGUGUGUCCGCCCCUUGUGUG-
3, was labeledwith [-32P]ATP (PerkinElmer) byT4polynucleotide kinase
(Promega).RNA-proteinbindingwas carriedout at roomtemperature in20
l of buffer (10mMHEPES, pH7.9, 5mMMgCl2, 40mMKCl, 1mMDTT, 5
g of nuclear proteins) for 30min. Heparin was added to a final concentra-
tion of 5g/l. For competition experiments, unlabeled cold RNA oligo at
50-fold molar excess was added 10 min before the addition of the radiola-
beledprobe.To identify specificproteins in theelectrophoreticmobility shift
assay (EMSA) complex, nuclear extracts were incubated with 2 g of anti-
body for 15min before addition of labeled probe. After incubation with the
labeled probe for an additional 30min, samples were subjected to native 6%
PAGE. For UV cross-linking, the RNA–protein binding mixture was UV
irradiated using a Spectrolinker XL-1000 UV Crosslinker (Fisher Scientific)
for 30 min and then resolved using 10% SDS-PAGE.
Animalmodels. Animal care and surgical procedures were approved by
the Animal Studies Committee of Washington University School of
Medicine (St. Louis, MO) in accordance with guidelines of the US Na-
tional Institutes ofHealth. Pregnant SpragueDawley damswere obtained
from Charles River at embryonic day 15. Rat pups of both sexes were
subjected to unilateral carotid ligation on postnatal day 7 (P7), followed
by hypoxia as described previously (Han et al., 2002). Briefly, under
halothane anesthesia the left carotid artery was exposed through an inci-
sion in the neck and cauterized. The incision was closed with skin glue
and the pups were allowed to recover from anesthesia in a 37°C chamber.
Figure 2. Bcl-xS knockdown attenuates apoptosis. A, Diagram shows Bcl-x pre-mRNA with
mRNA isoformsand shRNA specifically targeted at Bcl-xS. OP cellswere infectedwith a retroviral
vector expressing Bcl-xS shRNA or scramble shRNA for 48 h and then treated with C2-ceramide
(50M) for 16 h as described inMaterials andMethods. ss, splice site.B, RT-PCRwas performed
to analyze alternatively spliced Bcl-x isoforms (top), and total proteins were extracted and
analyzedbyWesternblot for Bcl-xL andBcl-xS (bottom).C, Cell deathwas assessedby LDHassay
and expressed as mean SE of three independent experiments. **p 0.01 compared to
scramble shRNA-treated OP cells.
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The pups were returned to the dam for 2 h for
refeeding and recovery after which they were
placed in chambers kept at 37°C throughwhich
humidified 8% oxygen (balance nitrogen)
flowed. After 2.5 h of hypoxia, the pups were
returned to the dam. At various time points (3,
6, 12, and 24 h) after the end of the hypoxia,
animals were killed and perfusedwith PBS. The
hippocampus and cortex were dissected on ice
and immediately frozen on dry ice.
Lentiviral vector production and hippocampal
injection. The above mentioned Bcl-xS shRNA
or control shRNA was inserted into pRRLsin-
U6cass-PGK-EGFPppt plasmid (provided by
Mingjie Li, Hope Center for Neurological
Disorders viral core, Washington University
School of Medicine) with AarI sites. shRNA and
EGFP were driven by human U6 and PGK pro-
moter, respectively. Lentiviral vectors (LVs)were
generated by transfection of 293T cells by using
the four-plasmid system (LVplasmid constructs:
pMDLgpRRE, pCMV-G, and pRSV-rev). Cul-
ture supernatants were harvested 48 h after
transfection, passed through a 0.45m filter,
concentrated by ultracentrifugation through a
20% sucrose cushion, and stored at80°C. Vec-
tor titers were determined by transduction of
HT1080 cells and assayed for EGFP expression
using flow cytometry. Pups at P0were rested on a
bed of ice for anesthetization before being placed
in amodified stereotaxic holder. Twomicroliters
of lentiviral vectors (1 106 infectious particles)
were injected into lefthippocampususing the fol-
lowingcoordinates: anteroposterior, 1.6mm; lat-
eral,1.4 mm; and ventral,2.4 mm. H–I was
performed at P7.
Histology. One week after H–I, animals were
perfused with PBS followed by 4%paraformal-
dehyde. The brains were removed, postfixed
overnight, cryoprotected in PBS containing
30% sucrose at 4°C until submerged, and then
embedded and frozen in OCT compound.
Twenty-five micrometer coronal sections were
cut on a freezing–sliding microtome and
mounted on slides. Sections were stained with
cresyl violet asdescribedpreviously (Holtzmanet
al., 1996). Eight corresponding sections for each
animal were scanned using aNanoZoomer high-
resolution whole-slide scanner (Hamamatsu),
and the volume of hippocampus and cortexwere
calculated. The percent volume loss in the le-
sioned versus the unlesionedhemispherewas de-
termined. Brain sections that strongly expressed
EGFP in the hippocampus were selected for analysis.
Immunostaining. Fixed cells or brain sections were washed with PBS
and permeabilized with 0.3% Triton X-100 in PBS for 20 min. Cells or
sections were incubated with anti-monoclonal CUGBP1 antibody over-
night at 4°C and then with goat anti-mouse secondary antibody (Alexa
Fluor 488, Invitrogen) for 1 h. For double labeling, terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay
(Millipore Bioscience Research Reagents) was performed to evaluate cell
death followed by immunofluorescence staining with CUGBP1 antibody
and Cy3-conjugated goat anti-mouse secondary antibody. Slides were
mounted in Vectashield with DAPI (Vector Laboratories) and examined
with a fluorescent microscope (Zeiss).
Statistical analysis. Values were expressed as mean  SE. Differences
between two groups were analyzed by Student’s t test, andmore than two
groups were analyzed by one-way ANOVA followed by post hoc Tukey’s
test.
Results
Bcl-x pre-mRNA splicing is a critical regulatory process in
neural cell apoptosis
We have previously demonstrated that ceramide, a lipid second
messenger implicated in cell death pathways, induces apoptosis
in OP cells (Lee et al., 2004), which are particularly vulnerable to
hypoxic–ischemic brain injury in the neonatal period (Back et al.,
2002). To determine whether alternative splicing of Bcl-x pre-
mRNA is an important regulatory process in OP cell death, cells
treated with C2-ceramide (C2) for 24 h, were assessed for Bcl-xL
and Bcl-xS mRNAs and cell death. C2 induced a dose-dependent
alteration in Bcl-x mRNA isoforms; changes in Bcl-xL/Bcl-xS ra-
tios occurred at lower concentrations of C2 than that which in-
duced cell death (LDH release, Fig. 1A). Similar changes in Bcl-x
Figure 3. UG rich elementsmodulate alternative splicingof Bcl-x.A, Shown is the structure of theBcl-xminigene constructwith
positions of the primers used to amplify minigene-specific mRNA products. The figure also depicts the PCR fragments obtained
from Bcl-x minigene-transfected HeLa and C6 glioma cells. B, Wild-type (W) and truncated minigenes (D1–D5) shown on the left
result in dramatically different Bcl-xL/Bcl-xS ratios (right). The numbers above each deletion construct indicate the distance
downstream of the Bcl-xL 5 splice site (ss). C, Thewild-type (W) and UGmotif-deletedminigenes (22 bp deletion, dUG) alters the
ratio of Bcl-xL/Bcl-xS in HeLa and C6 cells, favoring Bcl-xS expression. D, Single (M1) or double (M2) mutations in the UG motifs
resulted in a decrease of Bcl-xL/Bcl-xS ratios. Data were expressed as mean SE from three independent experiments.
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protein isoforms were also observed (Fig. 1C). A time course of
cells treated with 50 M C2 revealed that Bcl-x splicing changes
occurred early (within 1 h; Fig. 1B) compared to caspase-3 acti-
vation (first detected 8 h after treatment; Fig. 1D), DNA ladder-
ing (24 h; Fig. 1E), and cell death (24 h; Fig. 1F). Similar changes
in splicing were observed in OP cells treated with the general
protein kinase inhibitor staurosporine, and both apoptotic stim-
uli altered Bcl-x mRNA splicing in C6 glioma cells (data not
shown). Furthermore, primary cortical neurons treated with C2-
ceramide, staurosporine, or oxygen–glucose deprivation dem-
onstrated similar changes in Bcl-x splicing, decreasing Bcl-xL
while increasing Bcl-xS (Fig. 1G). These data suggest that recip-
rocal Bcl-x alternative splice changes occur widely in neural cells
induced by a variety of apoptotic stimuli.
Though overexpression of Bcl-xS results in cell death in many
in vitro paradigms (Lindenboim et al., 2001; Mitra et al., 2001),
the converse experiment (i.e., the effect of selective decrease of
endogenous Bcl-xS on cell death) has never been performed. We
designed an shRNA to selectively knock down Bcl-xS expression
by targeting the Bcl-xS 5 splice site (Fig. 2A). Knockdown re-
sulted in a75% decrease in Bcl-xS mRNA and protein without
altering Bcl-xL levels (Fig. 2B). This knockdown resulted in the
attenuation of cell death induced by C2 (Fig. 2C), indicating a
critical role for Bcl-xS in apoptosis.
CUGBP1 regulates Bcl-x splicing and subsequent cell death
Because Bcl-xL and Bcl-xS are both critical regulators of apopto-
sis, the modulation of Bcl-x alternative splicing is likely to have
profound effects on cell death. To elucidate cis-regulatory ele-
ments influencing Bcl-x pre-mRNA alternative splicing, a rat
bcl-x minigene was constructed (Fig. 3A). Transfection of this
minigene into both HeLa and C6 glioma cells (to ensure that
effects were not cell-line-specific) resulted in the generation of
Bcl-xL and Bcl-xS minigene-specific transcripts (Fig. 3A). A series
of progressively larger deletions within intron 2 were created to
identify critical cis-regulatory sequences near the Bcl-xL 5 splice
site. The serial deletions resulted in changes in the ratio of
Bcl-xL/Bcl-xS mRNA (Fig. 3B). We decided to pursue the non-
overlapping deletion between D4 and D5
(a 22-bp segment) because of its dramatic
effect on alternative splicing (favoring
Bcl-xS expression) and its close proximity
to the Bcl-xL 5 splice site. Isolated dele-
tion of this 22-bp sequence confirmed the
importance of this sequence in regulating
Bcl-x alternative splicing, demonstrating
dramatic shifts toward Bcl-xS expression
(Fig. 3C). Further analysis of the deleted
sequence revealed two adjacent UG-rich
sequences. Point mutations in the proxi-
mal UG motif resulted in a threefold de-
crease in the Bcl-xL/Bcl-xS ratio, while
double mutations in both motifs resulted
in a similar decrease in the ratio (Fig. 3D),
indicating the importance ofUGmotifs in
Bcl-x splice site selection. In addition to
the UG-rich element, we identified two
other intronic splicing enhancer consen-
sus sequences between bp 296 and 1508
(Fig. 3B). One of the consensus sequences
(GGGGG) is known to bind heteroge-
neous nuclear ribonucleoproteins (hn-
RNP F/H), while the other (UGCAUG)
binds to the Fox1/2 family. Further investigation is needed to
explore the role of these factors in the regulation of Bcl-x splicing.
TheUG-richmotifs in intron 2 constitute a consensus binding
sequence for a family of RNA binding proteins known as the
CELF (CUG-BP and ETR-3-like factor) family, which is known
to regulate alternative pre-mRNA splicing (Barreau et al., 2006;
Marquis et al., 2006). To identify trans-regulatory factors binding
to this UG-rich motif, RNA EMSAs were performed. OP cell
nuclear extracts were incubated with radiolabeled oligonucleo-
tides containing theUG-richmotif, cross-linked byUVexposure,
and electrophoresed. Two bands migrating at 50 kDa were
identified and eliminated when incubated with an excess cold
RNA probe indicating binding specificity (Fig. 4A). The EMSA
was probed with antibodies to two members of the CELF family,
CUGBP1 (CUG-binding protein 1) and ETR-3 (elav-type ribo-
nucleoprotein 3), to identify specific proteins in the EMSA com-
plex. Binding activity was eliminated with the CUGBP1 antibody
but not the ETR-3 antibody (Fig. 4B). A mutated probe with
double point mutations in the UG motifs (similar to that used in
Fig. 3D) lacked RNA binding activity, confirming specificity of
binding (Fig. 4C). Calf intestinal alkaline phosphatase treatment
eliminated the binding activity, suggesting that activity was reg-
ulated by phosphorylation (Fig. 4D). These findings suggest that
CUGBP1 specifically binds to theUG-richmotif near the 5 splice
site of Bcl-xL, and that its binding is regulated by phosphoryla-
tion. In agreement, the molecular weight of the factor in the UV
cross-linking experiments (49–51 kDa; Fig. 4A) is identical to the
known molecular weights of CUGBP1 (hyper- and hypo-
phosphorylated isoforms) (Timchenko et al., 1996).
Next, we examined CUGBP1 subcellular expression using im-
munocytochemistry, subcellular fractionation, and Western
blotting. Under basal conditions, CUGBP1 was found promi-
nently in the nucleus; however, after C2 treatment nuclear
CUGBP1 content decreased over time (Fig. 5A,F). After 24 h,
CUGBP1 immunoreactivity could be detected in only a few
nuclei (Fig. 5A–C). Double-labeling with CUGBP1 immuno-
staining and TUNEL showed that virtually all of the
TUNEL(	) cells had exclusive cytoplasmic CUGBP1 localiza-
Figure 4. CUGBP1binds to theUG-rich elements of Bcl-x pre-mRNA. Fivemicrogramsof nuclear extractswereprepared fromOP
cells and subjected to EMSA by reacting with a 32P-labeled UG rich RNA probe. Fiftyfold excess, unlabeled, nonspecific RNA or
specific cold RNA samples were included to show specificity of the RNA–protein complex. A, B, UV cross-linking (as described in
Materials and Methods) was performed to analyze the molecular weight of trans-acting factor bound to UG probe (A, star ()
indicates free probe). CUGBP1, but not ETR-3 antibodies eliminated the binding complex (B). C, A mutant probe (UGAC, similar
to that used in Fig. 3D) does not form the complex.D, Abrogation of binding is shownwhen nuclear extractswere treatedwith calf
intestinal alkaline phosphatase (CIP).
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Figure 5. Alterations in subcellular CUGBP1 distribution affect Bcl-x splicing and cell death. OP cells were treated with C2-ceramide (50 M) for varying times as indicated. A,
Immunocytochemistry reveals that nuclear CUGBP1 rapidly decreases after treatment with C2-ceramide (top, CUGBP1 immunostaining, green; bottom, overlay of CUGBP1 immuno-
staining, green, and DAPI staining, blue). B, Double-labeling with CUGBP1 immunostaining (red) and TUNEL (green) after C2-ceramide treatment demonstrates that virtually all
TUNEL(	) cells had cytoplasmic CUGBP1. C, D, Subcellular localization of CUGBP1 (C) and TUNEL(	) cells (D) were quantified and expressed as mean SE. from three independent
experiments. **p 0.01 compared to 0 h control (ANOVA with post hoc Tukey’s test). Nuc, Nucleus; Cyto, cytosol. E, Nuclear extracts from OP cells after ceramide treatment demonstrate
decreased UG-rich RNA binding using EMSA. F, Western blots from subcellular fractions of OP cells after ceramide treatment (top) confirm the decrease in nuclear CUGBP1. Blots were
quantified by densitometry, normalized to actin, and expressed as mean SE from three independent experiments (bottom), **p 0.01 compared to nuclear or cytosol control (ANOVA
with post hoc Tukey’s test). G, OP cells were transfected with CUGBP1 or vector constructs. H, CUGBP1 was knocked down using RNAi. At 24 h post-transfection, ceramide was added to
the cell culture for an additional 16 h. Overexpression and knockdown of CUGBP1 were verified by Western blot (top), alternatively spliced Bcl-x forms were determined by RT-PCR (middle
panel), and cell death was assessed by LDH assay (bottom). *p 0.05 si-CUGBP1 versus si-scramble, **p 0.01 CUGBP1 construct versus vehicle construct, or si-CUGBP1	ceramide
versus si-scramble	ceramide (ANOVA with post hoc Tukey’s test). Scale bars, 20m.
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tion, and TUNEL() cells showed progressively more cytoplas-
mic CUGBP1 with time (Fig. 5B–D). Consistent with these
findings, nuclear CUGBP1 RNA-binding activity decreased rap-
idly after C2 treatment (Fig. 5E). To further examine its regu-
latory role in Bcl-x splicing following injury, CUGBP1 was
overexpressed in OP cells. Compared to pcDNA3.1, ectopic ex-
pression of CUGBP1 increased Bcl-xL and decreased Bcl-xS, re-
sulting in decreased vulnerability to C2 treatment (Fig. 5G).
Furthermore, knockdown of CUGBP1 using siRNA resulted in a
decrease in the Bcl-xL/Bcl-xS ratio and an increase in C2-induced
cell death (Fig. 5H). These data indicate that CUGBP1 regulates
Bcl-x pre-mRNA splicing and thereby regulates cell death.
Effects of Bcl-x alternative splicing in
neonatal hypoxia-ischemia
Unilateral H–I in neonatal rats induces well characterized brain
injury within the ipsilateral cortex and hippocampus (Fig. 6A)
with prominent features of apoptosis (Pulera et al., 1998; Naka-
jima et al., 2000). To determine whether H–I resulted in altera-
tions in Bcl-x pre-mRNA splicing, P7 rats subjected to unilateral
H–I were killed at various times after H–I.
Within 3–6 h after H–I, the Bcl-xL/Bcl-xS
ratio was decreased in the ischemic hip-
pocampus and cortex compared to the
contralateral side (Fig. 6B–E). Further de-
creases in the Bcl-xL/Bcl-xS ratio were ob-
served up to 24 h afterH–I. Shamoperated
rats demonstrated no changes in this ratio
(between hemispheres). In both hippocam-
pus and cortex, caspase-3 activation oc-
curred at later time points (12 and 24 h),
suggesting that the Bcl-x pre-mRNA splic-
ing changes preceded this downstreamapo-
ptotic event (Fig. 6F,G).
To test whether knocking down Bcl-xS
results in neuroprotection in neonatal
H–I brain injury, a recombinant lentiviral
vector carrying Bcl-xS shRNAwas directly
injected into left anterior hippocampus of
the newborn rat. An EGFP gene driven by
a PGK promoter in the same vector dem-
onstrated robust fluorescence in the hip-
pocampus 1week after injection (Fig. 7A),
indicating successful LV-mediated gene
transfer. At P7, animals were subjected to
unilateral H–I, and killed 1 week later.
Compared to scrambled shRNA, the Bcl-xS
shRNA decreased Bcl-xS without signifi-
cantly altering Bcl-xL levels in the
LV-injected hippocampus (Fig. 7B). As
expected, both Bcl-xL and Bcl-xS levels did
not change in the cortex (Fig. 7C), dem-
onstrating the anatomic specificity of
LV-mediated shRNA knockdown. H–I re-
sulted in significant brain tissue loss both in
the hippocampus and cortex when assessed
1week afterH–I (Fig. 7D–F). Bcl-xS shRNA
reduced tissue loss by 47% in the ischemic
hippocampus compared to the scrambled
shRNA group; as expected, cortical loss was
not significantly different between the two
groups (Fig. 7D–F). Thus, Bcl-xS-specific
knockdown protected brain tissue against
H–I-induced cell death, indicating its important role in neural cell
injury independent of Bcl-xL effects.
Hypoxia–ischemia alters CUGBP1 expression concomitant
with Bcl-x splicing changes
We next sought to determine whether CUGBP1 expression and
subcellular localization were altered after neonatal H–I. RNA
EMSA showed a marked decrease of CUGBP1 binding activity in
cortical nuclear extracts 3 h after H–I compared to the contralat-
eral hemisphere and sham controls (Fig. 8A). These results were
confirmed by cell fractionation/Western blot and immunohisto-
chemistry that demonstrated reducedCUGBP1 expression in nu-
clei (Fig. 8B,C,E). The fractionation experiments did not show
changes in cytosolic levels of CUGBP1, although the immuno-
staining showed slightly higher levels in the cytoplasm after H–I
(Fig. 8B,D,E).
Discussion
Given the critical role of Bcl-xL in cell viability in the developing
and adult nervous system, it is not surprising that alternative
Figure6. Neonatalhypoxia-ischemiaaltersBcl-xalternative splicing.P7 ratsunderwentunilateral carotidartery ligationandexposure
tohypoxia for2.5handwerekilledatvarying times (3,6,12,and24h)afterhypoxia.A, The infarctedareaofa representativebrain section
is shownbyTTCstaining24hafterH–I.Arrows indicatecontralateral (C)or ischemic (I)hippocampusandcortexusedforRNAextraction.B,
C, Total RNA was extracted and analyzed by RT-PCR for alternative splicing of Bcl-x. A representative agarose gel of the RT-PCR products
fromhippocampus (B) or cortex (C) is shown (C, Contralateral hemisphere; I, ischemic hemisphere).D, E, Mean value SE of the Bcl-xL/
Bcl-xS ratio is fromhippocampus (D) andcortex (E) fromat least5animalspergroup.*p0.05,**p0.01 ischemicversus contralateral
(ANOVAwithpost hocTukey’s test).F,G,Westernblotswereperformedtomeasureactivatedcaspase-3 fromhippocampal (F )andcortical
(G) extracts (blots are representative of two independent replicates).
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splicing of Bcl-x pre-mRNA is tightly regulated under normal
physiological conditions. In this study, we demonstrate the im-
portance of splicing regulation in pathological CNS injury in vivo.
Bcl-x splicing is altered after neonatal H–I, resulting in increased
expression of Bcl-xS relative to Bcl-xL. These splicing changes
occurred earlier than downstream apoptotic events such as
caspase-3 activation and DNA fragmentation, suggesting an up-
stream regulatory role.Moreover, specifically knocking down the
Bcl-xS isoform (with concomitant changes in Bcl-x isoform ra-
tios) before H–I in neonatal rats resulted in attenuation of brain
injury. Previous studies have shown that overexpression of Bcl-xL
in similar H–I models also attenuates brain injury (Parsadanian
et al., 1998; Yin et al., 2006). Collectively, these data indicate that
the ratio of Bcl-x isoforms plays a critical role in brain injury and
suggest that the coordinate control of both isoforms via splicing
regulation may have additive or synergistic effects.
The pre-mRNA splicing machinery is extremely complex, in-
volving numerous cis-acting splicing sequences, trans-acting
splicing factors, interactions with transcription regulation, and
mRNAexport (Chen andManley, 2009). To identify cis-elements
and trans-factors, we created a Bcl-x minigene. Successive dele-
tionswithin intron 2 resulted in the identification of several splic-
ing enhancers and suppressors with profound effects on the ratio
of Bcl-xL/Bcl-xS mRNA (Fig. 3). A UG-rich element located
downstream of the Bcl-xL 5 splicing site was identified as an
important sequence for altering splicing, and CUGBP1 was
found to specifically bind to this sequence. In vitro and in vivo
studies revealed that nuclear CUGBP1 content was significantly
reduced after apoptotic stimulation. Furthermore, overexpres-
sion of CUGBP1 in vitro increased the Bcl-xL/Bcl-xS ratio, while
RNAi-mediated knockdown decreased the ratio.
CUGBP1 was first identified as a factor binding to pathologi-
cally expanded (CUG)n repeats in dystrophia myotonin protein
kinase (DMPK) mRNA found in patients with myotonic dystro-
phy (Timchenko et al., 1996; Roberts et al., 1997). In this disor-
der, pathogenesis is related in part to an increase in expression of
CUGBP1, resulting in disrupted regulation of alternative splic-
ing, mRNA translation, and mRNA stability (Philips et al., 1998;
Ranum and Cooper, 2006). CUGBP1 has been reported to regu-
late alternative splicing of a variety of genes (Philips et al., 1998;
Gromak et al., 2003; Dansithong et al., 2005; Ho et al., 2005) via
binding toUG orUGUmotifs (Faustino and Cooper, 2005;Mar-
quis et al., 2006). It is post-translationally regulated by phosphor-
ylation that alters RNA binding activity, increases nuclear
localization, and enhances splicing activity (Roberts et al., 1997).
Our findings of altered subcellular distribution and RNA-
binding activity of CUGBP1 following H–I are consistent with
these known regulatory pathways. CUGBP1/ mice have been
generated, but a significant proportion of the animals do not
survive past the first fewdays of life. These animals display growth
retardation and impaired fertility due to increased apoptosis of
germ cells (Kress et al., 2007). Overexpression of CUGBP1 has
Figure 7. Knockdown of Bcl-xS attenuates brain injury following H–I. Lentiviral vectors carrying Bcl-xS shRNA or scrambled (Scram) shRNA were injected into the left hippocampus of P0 rats. A,
A representative example of gene transfer is shown by detecting EGFP expression 1 week after injection. B, C, Animals were subjected to H–I at P7 and killed at P14. Bcl-xL and Bcl-xS mRNA levels
from the hippocampus (B) and cortex (C)were determined by RT-PCR (mean SE from5 animals).D, E, Representative cresyl-violet-stained brain sections from rats fromeach group (D, scrambled
shRNA:n
17;E, Bcl-xS shRNA:n
18) are shown. C, Contralateral hemisphere; I, ischemic hemisphere.F, Bcl-xS shRNA significantly reduced tissue loss in hippocampuswhere shRNAwas targeted
but not cortex (mean SE; *p 0.01 Bcl-xS shRNA versus scrambled shRNA).
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been shown to suppress the rCGG-induced neurodegeneration
in a transgenic Drosophila model of Fragile X-associated tremor/
ataxia syndrome (FXTAS) (Sofola et al., 2007), adding support to
a possible role for CUGBP1 in cell death. In the current study, we
report a direct link between CUGBP1 and Bcl-x pre-mRNA al-
ternative splicing, with a resultant impact on apoptosis.
Though targeting regulators of pre-mRNA splicingmay result
in wide-spread changes in RNA splicing, further study might
elucidate a target that specifically regulates cell death pathways.
Indeed, several studies have shown that “master switch” splicing
regulators may coordinately regulate specific unified functions
such as synapse-interacting proteins encoded by Nova RNA tar-
gets (Ule et al., 2005). Because of the antagonistic activities of the
two Bcl-x isoforms, the splicing machinery serves as an attractive
therapeutic target in which a single manipulation may coordi-
nately alter the expression of both pro- and anti-apoptotic pro-
teins. Several other apoptotic genes appear to undergo alternative
splicing, resulting in mRNA isoforms with antagonistic roles,
such asMcl-1, caspase-2 and -9, and adaptor proteins Apaf-1 and
IG20 (Wang et al., 1994; Jiang et al., 1998; Seol and Billiar, 1999;
Bae et al., 2000; Bingle et al., 2000; Al-Zoubi et al., 2001; Efimova
et al., 2004).
In summary, through both in vitro and in vivo neural injury
models, we have found that regulation of Bcl-x alternative splic-
ing modulates neural cell death. Our re-
sults suggest that alternative splicing may
be an important regulatory mechanism
for apoptosis after acute neurological in-
jury, and that splicing regulators may be
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